Marinus Pharmaceuticals Inc
MRNS
Get informed when a big investor buys or sells
+ FollowMarket Cap$30.37M
Close$
$12.31
2137.8% upside
Current Fair Value
2137.8% upsideUndervalued by 2137.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $30.37 Million |
|---|---|
| Enterprise Value | $43.37 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.63 |
| Beta | 1.26 |
| Outstanding Shares | 57,229,229 |
Return
| Return on Equity | 210.50% |
|---|---|
| Return on Assets | -220.81% |
| Return on Invested Capital | -421.10% |
Valuation & Multiples
| P/E Ratio | -0.21 |
|---|---|
| PEG | 0.79 |
| Price to Sales | - |
| Price to Book Ratio | -0.28 |
| Enterprise Value to Revenue | 1.38 |
| Enterprise Value to EBIT | -0.35 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.27 |
| Debt to Equity | -0.83 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 10, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▲ 0.01% |
|---|---|
| Total Invested | $3,239 |
| Investors Holding | 1▲ 1.00% |
ESG Score
No data
About Marinus Pharmaceuticals Inc
69 employeesMarinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-chara...